# Penicillins, a process for their preparation and compositions containing them.

## Abstract
A compound of formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof

## Claims
ACLAIMS 1 A compound of formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof EMI19.1 wherein R1 represents a hydrocarbon or heterocyclyl group R4 is a sub group of formula X or Y EMI19.2 wherein R2 is hydrogen or C16 alkyl and R3 is a sub group of formula A S R5 A wherein R5 is an aryl group or a C16 alkyl group substituted by an aryl group or R3 is a sub group of formula B NH R6 B wherein R6 is an optionally substituted C16 alkyl, aryl or cycloalkyl group. 2 A compound as claimed in claim 1 wherein R1 is phenyl, 4 hydroxyphenyl, or a 5 or 6 membered heterocyclic ring containing up to three heteroatoms selected from oxygen, sulphur or nitrogen, optionally substituted with hydroxy, amino, halogen or C1 6 alkoxy. 3 A compound as claimed in either of claims 1 or 2 wherein R6 is phenyl or C14 alkyl. 4 A compound as claimed in any of claims 1 3 wherein R2 is hydrogen. 5 613 2 3 Benzylamino 1,2,4 triazine 5 one 6 carbonylamino 2 phenyl acetamido penicillanic acid 6B t2 3 anilino 1,2,4 triazine 5 one 6 carbonyl amino 2 phenyl acetamido penicillanic acid 63 2 3 butylamino 1,2,4 triazine 5 one 6 carbonylamino 2 phenyl acetamido penicillanic acid or pharmaceutically acceptable salts or in vivo hydrolysable esters thereof. 6 A process for the preparation of a compound as claimed in claim 1, which process comprises A reacting a compound of formula II EMI21.1 wherein the amino group is optionally substituted with a group which permits acylation to take place, R1 is as defined with respect to formula I and any reactive substituents may be protected, and Rx is hydrogen or a carboxyl blocking group, with an N acylating derivative of an acid of formula III EMI21.2 wherein R4 is as defined with respect to formula I above and any reactive groups may be protected B by reacting a compound of formula V EMI22.1 wherein the amino group is optionally substituted with a group which permits acylation to take place and Rx is as defined with respect to formula II above, with anN acylating derivative of an acid of formula VII EMI22.2 wherein R1 and R4 are as defined with respect to formula I and any reactive groups therein may be protected and after steps A or B, if necessary carrying out one or more of the following steps i removing any carboxyl blocking group Rx ii removing any protecting groups on the sidechain group iii converting the product into a salt or in vivo hydrolysable ester thereof. 7 A process for the preparation of compounds claimed in claim I wherein R4 is of the sub group of formula B , which process comprises reacting a compound of formula VIII EMI23.1 wherein R1, R4 and Rx are as hereinbefore defined and wherein R3 is SR5 any reactive groups within compounds of formula VIII may be protected, with a compound of formula IX R6 NH2 IX wherein R6 is as hereinbefore defined and thereafter, if necessary, carrying out one or more of the following steps i removing any carboxyl blocking group Rx ii removing any protecting groups on the side chain group iii converting the product into a salt or in vivo hydrolysable ester thereof. 8 A composition which comprises a compound as claimed in any one of claims 1 to 5 together with a pharmaceutically acceptable carrier or excipient. 9 A composition as claimed in claim 8 which also comprises a B lactamase inhibitor. 10 A compound as claimed in any of claims 1 to 5 for use in the treatment of antibacterial infections in the human or animal body.

## Description
PENICILLINS, A PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM This invention relates to a class of penicillins which have antibacterial activity and are of value in the treatment of infections in animals, including mammals and especially humans. In particular the invention relates to Ã¢ class of penicillins with the 1,2,4 triazine group in the side chain. The invention also relates to a process for the preparation of such compounds, and to pharmaceutical compositions comprising them. The present invention provides a compound of formula I or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof EMI1.1 wherein R1 represents a hydrocarbon or heterocyclyl group R4 is a sub group of formula X or Y EMI2.1 wherein R2 is hydrogen or C1 6 alkyl and R3 is a sub group of formula A S R5 A wherein R5 is an aryl group or a C16 alkyl group substituted by an aryl group or R3 is a sub group of formula B NH R6 B wherein R6 is an optionally substituted C16 alkyl, aryl or cycloalkyl group.Certain compounds within formula I may also occur in two or more tautomeric forms these are also included within the scope of the present invention. Examples of suitable pharmaceutically acceptable in vivo hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or its salts, for example acyloxyalkyl groups, such as acetoxymethyl, pipaloyloxymethyl, a acetoxyethyl and a pivaloyloxyethyl groups alkoxycarbonyloxyalkyl groups, such as ethoxycarbonyloxymethyl and ethoxycarbonyloxyethyl dialkylaminoalkyl groups, such as dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl or diethylaminoethyl and lactone groups such as phthalidyl or dimethoxyphthalidyl. Suitable pharmaceutically acceptable salts of the compounds of formula I include metal salts, eg aluminium, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy lower alkylamines such as 2 hydroxyethylamine, bis 2 hydroxyethyl amine or tri 2 hydroxyethyl amine, cycloalkylamines such as dicyclohexylamine, or with procaine, dibenzylpiperidien, N benzyl phenethylamine, dehydroabietylamine, N,N bisdehydroabietylamine, ethylenediamine, or bases of the pyridine type such as pyridine, collidine or quinoline. The carbon atom marked in formula I is asymmetric and the compound may be derived from the side chain having a D, L or DL configuration at that position. All forms of compound I are included in this invention. Suitably, the carbon atom marked is derived from the D configuration and is conveniently referred to as the D penicillin. The term hydrocarbon includes groups having up to 18 carbon atoms, suitably up to 10 carbon atoms, conveniently up to 6 carbon atoms. Suitable hydrocarbon groups include C16 alkyl, C26 alkenyl, C26 alkynyl, C37 cycloalkyl, C37 cycloalkyl C1 6 alkyl, aryl, and aryl C1 6 alkyl, When used herein the term aryl includes phenyl and naphthyl optionally substituted with up to five halogen, C16 alkyl, C16 alkoxy, halo C1 6 alkyl, hydroxy, amino, carboxy, C16 alkoxycarbonyl, or C16 alkoxycarbonyl C1,6 alkyl groups. The term heterocyclyl includes single or fused rings comprising up to four hetero atoms in the ring selected from oxygen, nitrogen and sulphur and optionally substituted with up to three halogen, C1 6 alkyl, C16 alkoxy, halo C1 6 alkyl, hydroxy, amino, carboxy, C1 6 alkoxycarbonyl, C1 6 alkoxycarbonyl C1 6 alkyl, aryl or oxo groups. Suitably R1 in formula I is phenyl, 4 hydroxyphenyl, or a 5 or 6 membered heterocyclic ring containing up to three heteroatoms selected from oxygen, sulphur or nitrogen, optionally substituted with hydroxy, amino, halogen or C16 alkoxy. Suitably R1 is phenyl, 4 hydroxyphenyl, 2 thienyl, 3 thienyl or 2 amino 4 thiazolyl. Preferably R1 is phenyl or 4 hydroxyphenyl, especially phenyl. Preferably R2 is hydrogen. Suitable groups R6 include C16 alkyl optionally substituted by halogen, carboxy, C1 6 alkoxycarbonyl, carbamoyl, aryl, heterocyclyl, hydroxy, C16 alkanoyloxy, amino, mono and di C1 6 alkylamino, aryl, C16 alkylthio, C1 6alkyloxy and C37 cycloalkyl. Preferably R6 represents phenyl or C14 alkyl. When used herein the term lower refers to groups of up to six carbon atoms. Suitable C1 6 alkyl groups for R2, R5 and R6 may be straight or branched chain and include methyl, ethyl n or iso propyl, n , sec , iso or tert butyl. In those cases where the C16 alkyl group carries a substituent the preferred C1 6 alkyl groups for R5 andR6 include methyl, ethyl and n propyl. Preferred values of R3 within the present invention are those of formula B and include methylamino, ethylamino, butylamino, anilino, and 4 aminosulphonylphenylamino. Preferably R3 is anilino or butylamino. Particular compounds within formula I include 6B D,2 3 benzylamino 1,2,4 triazine 5 one 6 carbonyl amino 2 phenyljacetamido penicillanic acid 6B D,2 3 anilino 1,2,4 triazine 5 one 6 carbonyl amino 2 phenyl acetamido penicillanic acid 6B D,2 3 butylamino 1,2,4 tri zine 5 one 6 carbonyl amino 2 phenyl acetamido penicillanic acid. The compounds of formula I may be prepared by reacting a compound of formula II EMI5.1 wherein the amino group is optionally substituted with a group which permits acylation to take place, R1 is as defined with respect to formula I and any reactive substituents may be protected, and Rx is hydrogen or a carboxyl blocking group, with an N acylating derivative of an acid of formula III EMI6.1 wherein R4 is as defined with respect to formula I above and any reactive groups may be protected and thereafter, if necessary, carrying out one or more of the following steps i removing any carboxyl blocking groups RX ii removing any protecting groups on the side chain group iii converting the product into a salt or in vivo hydrolysable ester thereof. Suitable groups which permit acylation to take place and which are optionally present on the amino group of the starting material of the formula II include N silyl, N stannyl and N phosphorus groups, for example trialkylsilyl groups such as trimethylsilyl, trialkyltin groups such as tri n butyltin, groups of formula P.RaRb wherein Ra is an alkyl, haloalkyl, aryl, aralkyl, alkoxy, haloalkyl, aryl, aralkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy or dialkylamino group, Rb is the same as Ra or is halogen or Ra and Rb together form a ring suitable such phosphorus groups being P 0C2H5 2, P C2H5 2, EMI7.1 Suitable carboxyl blocking derivatives for the group CO2RX in formula II include salts and ester derivatives of the carboxylic acid.The derivative is preferably one which may readily be cleaved at a later stage of the reaction. Suitable salts include metal salts, such as those with sodium, potassium and lithium, and tertiary amine salts, such as those with trilower alkylamines, N ethylpiperidine, 2,6 lutidine, pyridine, N methylpyrrolidine, dimethylpiperazine. A preferred salt is with triethylamine. Suitable ester forming carboxyl blocking groups are those which may be removed under conventional conditions. Such groups for Rx include benzyl, p methoxybenzyl, 2, 4, 6 trimethylbenzyl, 3,5 di t butyl 4 hydroxy benzyl, benzoylmethyl, p nitrobenzyl, 4 pyridylmethyl, 2,2,2 trichloroethyl, 2,2,2 tribromoethyl, t butyl, t amyl, diphenylmethyl, triphenylmethyl, adamantyl, 2 benzyloxyphenyl, 4 methylthiophenyl, tetrahydrofur 2 yl, tetrahydropyran 2 yl, pentachlorophenyl, p toluenesulphonylethyl, methoxymethyl, a silyl, stannyl or phosphorus containing group, such as described above, an oxime radical of formula N CHRO where Ro is aryl or heterocyclic, or an in vivo hydrolysable ester radical such as defined above. The carboxyl group may be regenerated from any of the above esters by usual methods appropriate to the particular Rx group, for example, acid and base catalysed hydrolysis, or by enzymically catalysed hydrolysis, or by hydrogenation. A reactive N acylating derivative of the acid III is employed in the above process. The choice of reactive derivative will of course be influenced by the chemical nature of the substituents of the acid. Suitable N acylating derivatives include an acid halide, preferably the acid chloride or bromide.Acylation with an acid halide may be affected in the presence of an acid binding agent for example, tertiary amine such as triethylamine or dimethylaniline , an inorganic base such as calcium carbonate or sodium bicarbonate or an oxirane, which binds hydrogen halide liberated in the acylation reaction. The oxirane is preferably a C1 6 1,2,alkylene oxide such as ethylene oxide or propylene oxide. The acylation reaction using an acid halide may be carried out at a temperature in th range 5O0C to 500C, preferably 200C to 200C, in aqueous or non aqueous media such as aqueous acetone, aqueous tetrahydroform, ethyl, acetate, dimethylacetamide, dimethylformamide, acetonitrile, dichloromethane, 1,2 dichloroethane, or mixtures thereof.Alternatively, the reaction may be carried out in an unstable emulsion of water immiscible solvent, especially an aliphatic ester or ketone, such as methyl isobutyl ketone or butyl acetate. The acid halide may be prepared by reacting the acid III or a salt thereof with a halogenating eg chlorinating or brominating agent such as phosphorus pentachloride, thionyl chloride or oxalyl chloride. Alternatively, the N acylating derivative of the acid III may be a symmetrical or mixed anhydride.Suitable mixed anhydrides are alkoxyformic anhydrides, or anhydrides with, for example, carbonic acid monoesters, trimethyl acetic acid, thioacetic acid, diphenylacetic acid, benzoic acid, phosphorus acids such as phosphoric or phosphorous acids or aliphatic or aromatic sulphonic acids such as p toluenesulphonic acid . When a symmetrical anhydride is employed, the reaction may be carried out in the presence of 2,6 lutidine as catalyst. Alternative N acylating derivatives of acid III are the acid azide, or activated esters such as esters with 2 mercaptopyridine, cyanomethanol, p nitrophenol, 2,4 dinitrophenol, thiophenol, halophenols, including pentachlorophenol, monomethoxyphenol, N hydroxy succinimide, or 8 hydroxyquinoline or amides such asN acylsaccharins or N acylphthalimides or an alkylidene iminoester prepared by reaction of the acid III with an oxime. Other reactive N acylating derivatives of the acid III include the reactive intermediates formed by reaction in situ with a condensing agent such as a carbodiimide, for example, N,N diethyl , dipropyl or diisopropylcarbodiimide, N,N di cyclohexylcarbodiimide, or N ethyl N g dimethylaminopropyl carbodiimide a suitable carbonyl compound, for example, N,N carbonyldiimidazole or N,N carbonylditriazole an isoxazolinium salt, for example, N ethyl5 phenylisoxazolinium 3 sulphonate or N t butyl 5methylisoxazolinium perchlorate or an N alkoxycarbonyl 2 alkoxy 1,2 dihydroquinoline, such as N ethoxycarbonyl 2 ethoxy 1,2 dihydroquinoline. Other condensing agents include Lewis acids for example BBr3 C6H6 i or a phosphoric acid condensing agent such as diethylphosphorylcyanide.The condensation reaction is preferably carried out in an organic reaction medium, for example, methylene chloride, dimethylformamide, acetonitrile, alcohol, benzene, dioxan or tetrahydrofuran. The intermediate compound of formula 11 may be prepared by reacting a compound of formula V EMI10.1 wherein the amino group is optionally substituted with a group which permits acylation to take place and Rx is as defined with respect to formula II above, with anN acylating derivative of an acid of formula VI EMI10.2 wherein R1 is as defined with respect to formula I and any reactive groups therein may be protected and RY is an amino protecting group and thereafter removing protecting group RY. Suitable N acylating derivatives, carboxyl protecting groups and reaction conditions include those described hereinbefore. Suitable amino protecting groups RY are those well known in the art which may be removed under conventional conditions without disruption of the remainder of the molecule. The compounds of formula I may also be prepared by reacting a compound of formula V as described hereinbefore with an N acylating derivative of an acid of formula VII EMI11.1 wherein R1 and R4 are as defined with respect to formula I and any reactive groups therein may be protected and thereafter, if necessary, carrying out one or more of the following steps i removing any carboxyl blocking group Rx ii removing any protecting groups on the side chain group iii converting the product into a salt or in vivo hydrolysable ester thereof. Compounds within formula I wherein R4 is a sub group of formula B may also be prepared by reacting a compound of formula VIII EMI11.2 wherein R1, R4 and Rx are as hereinbefore defined and wherein R3 is SR5 any reactive groups within compounds of formula VIII may be protected, with a compound of formula IX R6 NH2 IX wherein R6 is as hereinbefore defined and thereafter, if necessary, carrying out one or more of the following steps i removing any carboxyl blocking group Rx ii removing any protecting groups on the side chain group iii converting the product into a salt or in vivo hydrolysable ester thereof. The antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibiotics, and the invention therefore includes within its scope a pharmaceutical composition comprising a compound of formula I above toqether with a pharmaceutical carrier or excipient. The composition may be formulated for administration by any route, such as oral topical or parenteral. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions. Tablets and capsules for administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone fillers, for example lactose, sugar, maize starch, calcium phosphate, sorbitol or glycine, tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica disintegrants, for example potato starch or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia non aqueous vehicles which may include edible oils for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol preservatives, for example methyl or propyl p hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents. Suppositories will contain conventional suppository bases, e.g. cocoa butter or other glyceride. For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.Advantageously, agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parental suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound. The compositions may contain from 0.1 by weight, preferably from 10 60 by weight, of the active material, depending on the method of administration.Where the compositions comprise dosage units, each unit will preferably contain from 50 500 mg of the active ingredient. The dosage as employed for adult human treatment will preferably range from 100 to 300 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. The compound of formula I may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics or with aB lactamase inhibitor may be employed. Advantageously, the compositions also comprise a compound of formula X or a pharmaceutically acceptable salt or ester thereof EMI14.1 wherein A is hydroxyl, substituted hydroxyl, thiol, substituted thiol, amino, mono or di hydrocarbylsubstituted amino, or mono or di acylamino. A further advantageous composition comprises a compound of formula I or a pharamceutically acceptable salt or in vivo hydrolysable ester thereof together with a compound of formula XI or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof EMI15.1 The present invention also provides a method of treating bacterial infections in animals, in particular humans or domestic mammals, which comprises the administration of a composition of this invention The following Examples illustrate the preparation of the compounds of this invention. Example 1 6B D,2 3 Anilino 1,2,4 triazine 5 one 6 carbonyl amino 2 phenyllacetamido penicillanic acid 3 Anilino 5 hydroxy 1,2,4 triazine 6 carboxylic acid 0.47g 0.002 mol dissolved in methylene dichloride 20 ml and triethylamine 1.5ml was cooled to 200C and treated with thionyl chloride 0.15 . The solution was stirred at 20 C for 1 hr and treated all at once with a solution of anhydrous ampicillin 0.7g.0.002 mol in methylene dichloride 20 ml and triethylamine 0.6ml cooled to 0 C. The reaction solution was stirred at RT for lhr and evaporated. The residue, dissolved in water 30 ml was washed with ether 2 x 30 ml , covered with ethylacetate 30 ml and acidified with shaking, to pH 1.5 with 5N hydrochloric acid. The insoluble material was separated, dissolved in methanol 20 ml treated with 2N sodium 2 ethyl hexanoate in methyl isobutyl ketone 1 ml and the solution evaporated to small volume. The residual oil was diluted with excess dry ether and the separated solid filtered washed well with dry ether and dried in vacuo to give the required penicillin sodium salt 0.39g 34.2 . 5 CD3 2 S0 D20 1.46 and 1.60 6H, 2s, gemdimethyls , 4.11 1H, s, w3 proton , 5.40 2H,ABq., B lactam protons , 6.02 1H, s, a proton , 7.00 8.00 5H, m, anilino protons 7.40 5H, m, phenyl protons . Rf BEW 0.35. Example 2 6B lDt2 3 Butylamino lt24 triazine 5 one 6 carbonyl amino 2 phenyllacetamido penicillanic acid. 3 n Butylamino 5 hydroxy 1,2,4 triazine 6 carbo xylic acid 0.26g 0.0012mol dissolved in methylene dichloride 20 ml and triethylamine lml was cooled to 20 C and treated with thionyl chloride 0.llml . The solution was stirred at 200C and treated all at once with a solution of anhydrous ampicillin 0.42g 0.0012mol in methylene dichloride 20 ml and triethylamine 0.4ml cooled to 0 C. The solution was stirred at RT for lhr and evaporated to dryness. The residue dissolved in water 20 ml was washed with ether 2 x 20ml covered with ethylacetate 20 ml and acidified, with shaking, to pH 1.5 with 5N hydrochloric acid. The aqueous layer was re extracted with ethyl acetate 20ml and the combined organic extracts dried over anhydrous magnesium sulphate.The dry solution was treated with 2N sodium 2 ethyl hexanoate in methyl isobutyl ketone 0.7ml . The separated solid was filtered, washed well with dry ether and dried in vacuo to give the required penicillin sodium salt 0.45g 66.4 . 5 CD3 2SO D20 0.84 3H, t, NHCH2 CH2 2CH3 , 1.20 4H, m, CH2 CH2 2CH3 , 1.45 and 1.57 6H, 2s, gemdimethyls , 3.28 2H, t, NHCH2 , 4.06 1H, s, C3 proton , 5.46 2H, q, B lactam protons , 5.97 lH, s, proton , 7.47 5H, m, aromatic protons RF BEY 0.40. BIOLOGICAL DATAEMI18.1 tb SEP Compound SEP of SEP Example SEP No. tb SEP ORGANISM SEP tb SEP 1 SEP 2 tb E.coli SEP ESS SEP 0.2 SEP 0.1 tb E. SEP coli SEP NCTC SEP 10418 SEP 12.5 SEP 5.0 tb Ps. SEP aeruginosa SEP NCTC tb SEP 10662 SEP 10 2 SEP 12.5 SEP 5.0 tb P SEP mirabilis SEP C977 SEP 12.5 SEP 2.5 tb B SEP subtilis SEP 0.5 SEP 0.5 tb S SEP aureus SEP Oxford SEP 0.1 SEP 0.5 tb N. SEP catarrhalis SEP 1502 SEP 0.02 SEP 0.02 tb S. SEP faecalis SEP I SEP 5.0 SEP 12.5 tb S. SEP pyogenes SEP CN SEP 10 SEP 1.2 SEP 0.05 tb